Frank Takanen

“Thank you for taking the questions and congrats on the progress and the new CEO appointment. On NanoKnife, I'd like to follow up on how you guys think about once the equipment is placed in the timeline to really scaling to a higher utilization rate.”

“I wanted to start with one on FDA interactions, maybe talk a little bit more about some of the conversations you've had, obviously, that you're comfortable sharing in a public setting, and then maybe detail what part of the process you're in with that clearance on 41.”

“Thank you for taking the questions. at the risk of getting a little over our skis, I was hoping to ask about 2027. I think where consensus sits today is about 23% top-line growth, and I've previously tagged the RNS business about 20% in line with your guys' commentary.”

“I've been hopping between a couple calls. I wanted to talk about free cash flow a little bit more. I know, Lance, you mentioned the $25 million AMDS is in Q3.”

“I wanted to follow up with a question on the strategic focus or change in strategic focus a little bit closer. or maybe walk us through in a little more granular detail the reorganization.”